<DOC>
	<DOCNO>NCT01723774</DOCNO>
	<brief_summary>A Phase II study investigate potential utility PD 0332991 treatment early stage ER+ Human epidermal growth factor receptor 2 ( HER2 ) - breast cancer , investigate whether combination PD 0332991 anastrozole able : 1 ) improve pathologic complete response rate compare historical control single agent aromatase inhibitor , 2 ) result few patient therapy Ki67 &gt; 10 % compare historical control .</brief_summary>
	<brief_title>PD 0332991 Anastrozole Stage 2 3 Estrogen Receptor Positive HER2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Preregistration PIK3CA Mutant Inclusion Clinical T2T4c , N , M0 invasive ER+ ( Allred Score 68 ) HER2 negative ( 0 1+ IHC FISH negative amplification ) breast cancer , AJCC 7th edition clinical staging , goal surgery completely excise tumor breast lymph node . Note : Patients invasive ER+ ( Allred Score 68 ) HER2 breast cancer DCIS contralateral breast patient eligible Female ≥18 year age ECOG performance status 0 , 1 2 Life expectancy &gt; 4 month Premenopausal , patient must willing comply pregnancy requirement Adequate organ marrow function leukocytes ≥ 3,000/mcL absolute neutrophil count ≥ 1,500/mcL platelet ≥ 100,000/mcL total bilirubin ≤ ULN AST ( SGOT ) / ALT ( SGPT ) &lt; 2.5 X ULN Creatinine ≤ ULN Able understand willing sign IRBapproved write informed consent document Exclusion Prior treatment cancer include : surgery , radiation , chemotherapy , biotherapy , hormonal therapy , investigational agent prior study entry Receiving investigational agent Prior therapy Cdk4 inhibitor Any follow previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , symptomatic pulmonary embolism Uncontrolled intercurrent illness include , limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled symptomatic cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant/nursing Unwilling employ adequate contraception Known HIVpositive combination antiretroviral therapy Evidence inflammatory cancer Known metastatic disease Current use anticoagulation therapy Previous excisional biopsy breast cancer sentinel lymph node biopsy Any condition impair patient 's ability swallow PD 0332991 tablet ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption ) History allergic reaction attribute compound similar chemical biologic composition PD 0332991 agent use study Corrected QT interval &gt; 470 msec Registration PIK3CA Mutant Inclusion The criterion must meet addition preregistration criterion , except treatment endocrine therapy cancer allow prior registration PIK3CA mutant cohort : tumor PIK3CA mutation present Premenopausal woman , serum estradiol level postmenopausal range ≤ 7 day prior registration Exclusion Criteria must meet addition preregistration criterion Current use anticipate need food drug know strong CYP3A4 inhibitor ( i.e . grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , posaconazole , erythromycin , clarithromycin , telithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , nefazodone , diltiazem , delavirdine ) inducer ( i.e . dexamethasone , glucocorticoid , progesterone , rifampin , phenobarbital , St. John 's wort ) PIK3CA Wild Type Inclusion Clinical T2T4c , N , M0 invasive ER+ ( Allred Score 68 ) HER2 negative ( 0 1+ IHC FISH negative amplification ) breast cancer , AJCC 7th edition clinical staging , goal surgery completely excise tumor breast lymph node . Note : Patients invasive ER+ ( Allred Score 68 ) HER2 breast cancer DCIS contralateral breast patient eligible For PIK3CA wild type cohort : tumor PIK3CA mutation absent . Note patient sufficient research tissue PIK3CA sequence preregistration PIK3CA sequence result delay , could register enrol PD991 trial without assign particular cohort time enrollment . PIK3CA sequence perform future tumor collect subsequent time point assign treatment cohort PIK3CA sequence data available For endocrine resistant cohort : Ki67 &gt; 10 % central test Washington University AMP laboratory tumor biopsy perform least 2 week neoadjuvant endocrine therapy . Note prior neoadjuvant endocrine therapy could include endocrine therapy ( include aromatase inhibitor , tamoxifen , fulvestrant ) alone combination , endocrine therapy combination investigational agent Cdk 4/6 inhibitor *Patients Day 17 Ki67 &gt; 10 % NCI9170 trial eligible endocrine resistant cohort Female &gt; 18 year age ECOG performance status 0 , 1 2 Life expectancy &gt; 4 month If premenopausal , patient must willing comply pregnancy requirement Adequate organ marrow function : leukocytes ≥ 3,000/mcL absolute neutrophil count ≥ 1,500/mcL platelet ≥ 100,000/mcL total bilirubin ≤ ULN AST ( SGOT ) / ALT ( SGPT ) &lt; 2.5 X ULN Creatinine ≤ ULN In premenopausal woman , serum estradiol level postmenopausal range ≤ 7 day prior registration . Able understand willing sign IRBapproved write informed consent document Exclusion Prior treatment cancer include : Surgery , Radiation therapy , Chemotherapy , Biotherapy , Hormonal therapy , Investigational agent prior study entry Receiving investigational agent Prior therapy Cdk4 inhibitor Any follow previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , symptomatic pulmonary embolism Uncontrolled intercurrent illness include , limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled symptomatic cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant/nursing Unwilling employ adequate contraception Known HIVpositive combination antiretroviral therapy Evidence inflammatory cancer Known metastatic disease Current use anticoagulation therapy Previous excisional biopsy breast cancer sentinel lymph node biopsy Any condition impair patient 's ability swallow PD 0332991 tablet ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption ) History allergic reaction attribute compound similar chemical biologic composition PD 0332991 agent use study Corrected QT interval &gt; 470 msec Current use anticipate need food drug know strong CYP3A4 inhibitor ( i.e . grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , posaconazole , erythromycin , clarithromycin , telithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , nefazodone , diltiazem , delavirdine ) inducer ( i.e . dexamethasone , glucocorticoid , progesterone , rifampin , phenobarbital , St. John 's wort ) Endocrine Resistant Inclusion Clinical T2T4c diagnosis screening , N , M0 invasive ER+ ( Allred Score least 3 &gt; 1 % ER positivity ) HER2 negative ( 0 1+ IHC FISH negative equivocal ) breast cancer , AJCC 7th edition clinical staging , goal surgery completely excise tumor breast lymph node . Note : Patients invasive breast cancer ER po , HER2 neg equivocal DCIS contralateral breast eligible ; multifocal disease exclude . The dominant lesion follow per protocol Ki67 &gt; 10 % central test Washington University AMP laboratory tumor biopsy perform least 2 week neoadjuvant endocrine therapy . If Ki67 &gt; 10 % local testing , Ki67 slide H &amp; E slide need review study pathologist confirm eligibility ( discuss Study Chair ) . For patient external Washington University , please contact Washington University coordinator email screen ID # assign prior shipment slide Female ≥ 18 year age ECOG performance status 0 , 1 2 Pre postmenopausal woman eligible . If premenopausal , patient must willing comply pregnancy requirement agree GnRH agonist therapy ovarian suppression study Adequate organ marrow function : Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin ≤ ULN AST ( SGOT ) / ALT ( SGPT ) &lt; 2.5 X ULN Creatinine ≤ ULN Able understand willing sign IRBapproved write informed consent document Exclusion Prior treatment cancer include : Surgery , Radiation , Chemotherapy Receiving investigational agent Prior therapy Cdk4 inhibitor Any follow previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , symptomatic pulmonary embolism Uncontrolled intercurrent illness include , limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled symptomatic cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant/nursing Unwilling employ adequate contraception Known HIVpositive combination antiretroviral therapy Known metastatic disease Current use anticoagulation therapy Previous excisional biopsy breast cancer sentinel lymph node biopsy Any condition impair patient 's ability swallow PD 0332991 tablet ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption ) History allergic reaction attribute compound similar chemical biologic composition PD 0332991 agent use study Corrected QT interval &gt; 470 msec Current use anticipate need food drug know strong CYP3A4 inhibitor ( i.e . grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , posaconazole , erythromycin , clarithromycin , telithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , nefazodone , diltiazem , delavirdine ) inducer ( i.e . dexamethasone , glucocorticoid , progesterone , rifampin , phenobarbital , St. John 's wort ) Adjuvant Inclusion Derived benefit PD 0332991 neoadjuvant set trial . This include 26 patient achieve complete cell cycle arrest addition PD 0332991 ( C1D1 Ki67 &gt; 2.7 % C1D15 Ki67 ≤ 2.7 % ) main study ( PIK3CA WT , mutant , unknown cohort ) well patient Ki67 ≤ 10 % C1D15 biopsy endocrine resistant cohort ECOG performance status 0 , 1 2 Premenopausal , patient must willing comply pregnancy requirement lay Adequate organ marrow function leukocytes ≥ 3,000/mcL absolute neutrophil count ≥ 1,500/mcL platelet ≥ 100,000/mcL total bilirubin ≤ ULN AST ( SGOT ) / ALT ( SGPT ) ≤ 2.5 X ULN Creatinine ≤ ULN Underwent surgery breast axilla curative intent At least 4 week post completion adjuvant chemotherapy radiation therapy indicate Patients already start adjuvant hormonal therapy eligible following condition : For 26 patient enrolled initial cohort derive benefit neoadjuvant PD 0332991 ( C1D1 Ki67 &gt; 2.7 % C1D15 Ki67 ≤ 2.7 % ) , adjuvant PD 0332991 initiate soon possible adjuvant hormonal therapy initiate patient complete radiation indicate For patient enrolled endocrine resistant cohort derive benefit neoadjuvant PD 0332991 ( C1D15 Ki67 ≤ 10 % ) , adjuvant PD 0332991 initiate within 6 month sooner initation adjuvant hormonal therapy Able understand willing sign IRBapproved write informed consent document Exclusion Any follow previous 6 month : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , symptomatic pulmonary embolism Uncontrolled intercurrent illness include , limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled symptomatic cardiac arrhythmia , ssychiatric illness/social situation would limit compliance study requirement Pregnant/nursing Unwilling employ adequate contraception Known HIVpositive combination antiretroviral therapy . Known metastatic disease Any condition impair patient 's ability swallow PD 0332991 tablet ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption ) History allergic reaction attribute compound similar chemical biologic composition PD 0332991 agent use study Corrected QT interval &gt; 470 msec Current use anticipate need food drug know strong CYP3A4 inhibitor ( i.e . grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , posaconazole , erythromycin , clarithromycin , telithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , nefazodone , diltiazem , delavirdine ) inducer ( i.e . dexamethasone , glucocorticoid , progesterone , rifampin , phenobarbital , St. John 's wort )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>